Chris Markoch

Chris Markoch

InvestorPlace Contributor

Chris Markoch is a freelance financial writer who brings over 25 years in sales and marketing to help find the story behind the stock. Chris starts by asking the question, “So what?” and then uses fundamental and (some) technical analysis to add depth to that insight.

Stepping back from the “what” allows Chris to bring perspective that helps investors make wise decisions based on their risk tolerance and investing timeline.

Markoch would describe his writing as being for investors more than traders. He looks at equities through a long-term lens and that is reflected in his writing.

In addition to his articles on InvestorPlace, you can also find Chris’ writing on MarketBeat.com where he has collaborated on the e-book “5 Investing Trends That Will Define the Market in 2022.” You can find Chris on LinkedIn and on Twitter.

Recent Articles

It’s Time For Growth Investors to Jump on Stem

By Chris Markoch, InvestorPlace Contributor

STEM stock has been up and down lately. But with growth investors looking for new opportunities, now is the time to jump on board.

Is Zomedica Making a Change For the Better?

By Chris Markoch, InvestorPlace Contributor

ZOM stock trades below $1 as investors wait to see if recent changes to the company's business model along with potential acquisitions can be a catalyst for revenue.

SOS Stock Simply Faces Too Many Obstacles

By Chris Markoch, InvestorPlace Contributor

SOS stock was falling before the recent selloff in cryptocurrencies. Recent financial results are encouraging, but the stock still looks overvalued.

Litecoin Is Worth a Look For Its Long-Term Viability

By Chris Markoch, InvestorPlace Contributor

Nobody can say predict the short-term outlook for cryptocurrencies. But if you look past the volatility, Litecoin is a sound option.

Clover Health Is Only For the Most Risk-Tolerant Investors

By Chris Markoch, InvestorPlace Contributor

Despite strong revenue numbers, CLOV stock is facing heavy short interest. But risk-tolerant investors may see it as a buying opportunity.

Ocugen Faces Long Odds Before Gaining From Its Covid-19 Support Role

By Chris Markoch, InvestorPlace Contributor

Ocugen has skin in the Covid-19 vaccine game. But the company faces long odds on its partnership providing a long-term boost for OCGN stock.

Fisker Announces Two Major Partnerships, But Is FSR Stock a Buy? 

By Chris Markoch, InvestorPlace Contributor

On the heels of two significant announcements that make its production goals more likely, it appears that FSR stock may have found a bottom.

Dogecoin Still Seems More Like a Craze Than a Currency

By Chris Markoch, InvestorPlace Contributor

DOGE is still one of the trendiest cryptocurrencies of 2021, but volatility and few places to spend it reduce Dogecoin's potential.

3 Reasons Why ChargePoint Stock Lacks Juice

By Chris Markoch, InvestorPlace Contributor

ChargePoint is likely to play a major role in the world’s EV future. But until it gets here, CHPT stock has some headwinds to overcome.

Don’t Look Now, but Nio Stock Is Becoming an Investment Not a Trade

By Chris Markoch, InvestorPlace Contributor

NIO stock is down 30% in 2021. As investors recalibrate their expectations for the EV sector, they keep raising the bar on the Tesla of China.

Load More